Caribou Biosciences (CRBU) Gains from Investment Securities (2020 - 2023)
Caribou Biosciences (CRBU) reported Gains from Investment Securities of $170000.0 for Q2 2023, down 79.62% year-over-year from $834150.0 in Q2 2022, and down 79.62% quarter-over-quarter from $834150.0 in Q2 2022.
Caribou Biosciences (CRBU) Gains from Investment Securities (2020 - 2023) Analysis & Trends
Caribou Biosciences (CRBU) has 4 years of Gains from Investment Securities data on file, last reported at $170000.0 in Q2 2023.
- Gains from Investment Securities for Q2 2023 came in at $170000.0, down 79.62% year-over-year; the trailing twelve-month figure through Sep 2024 was $170000.0 (changed 0.0% YoY), and the FY2025 annual result was $2.1 million, changed N/A from the prior year.
- Gains from Investment Securities fell to $170000.0 in Q2 2023 per CRBU's latest filing, from $834150.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $26.2 million in Q1 2022 and troughed at $10000.0 in Q4 2020.
- A 4-year average of $3.3 million and a median of $279699.0 in 2020 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities surged 1581.47% in 2022, then plunged 79.62% in 2023.
- A 4-year view of Gains from Investment Securities shows it stood at $10000.0 in 2020, then soared by 980.0% to $108000.0 in 2021, then jumped by 672.36% to $834150.0 in 2022, then sank by 79.62% to $170000.0 in 2023.
- Business Quant data shows CRBU's Gains from Investment Securities at $170000.0 in Q2 2023, $834150.0 in Q2 2022, and $26.2 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 170,000.00 |
| Jun 30, 2023 | 170,000.00 |
| Jun 30, 2022 | 834,150.00 |
| Jun 30, 2022 | 834,150.00 |
| Mar 31, 2022 | 26.25 Mn |
| Mar 31, 2022 | 26.25 Mn |
| Dec 31, 2021 | 108,000.00 |
| Dec 31, 2021 | 108,000.00 |
| Sep 30, 2021 | 138,420.00 |
| Sep 30, 2021 | 138,420.00 |
| Mar 31, 2021 | 1.56 Mn |
| Mar 31, 2021 | 1.56 Mn |
| Dec 31, 2020 | 10,000.00 |
| Dec 31, 2020 | 10,000.00 |
| Sep 30, 2020 | 379,761.00 |
| Sep 30, 2020 | 379,761.00 |
| Jun 30, 2020 | 279,699.00 |
| Jun 30, 2020 | 279,699.00 |